Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nucana PLC

0.4602
-0.0598-11.50%
Post-market: 0.4410-0.0192-4.17%16:03 EDT
Volume:513.51K
Turnover:240.25K
Market Cap:2.79M
PE:-0.06
High:0.5201
Open:0.5201
Low:0.4133
Close:0.5200
Loading ...

BRIEF-Nucana Reports Q3 2024 Financial Results And Provides Business Update

Reuters
·
25 Nov 2024

Nucana Reports Third Quarter Loss Amid R&D Investments

TIPRANKS
·
25 Nov 2024

NuCana Q3 2024 GAAP EPS Of £(0.07) Versus £(0.13) YoY, Cash And Cash Equivalents Of £11.4M Expected To Provide Cash Runway Into Q2 2025

Benzinga
·
25 Nov 2024

NuCana GAAP EPS of -£0.07

seekingalpha
·
25 Nov 2024

NuCana Plc: Qtrly Loss per Share £0.07

THOMSON REUTERS
·
25 Nov 2024

NuCana Plc: Anticipated Cash Runway Into Q2 2025

THOMSON REUTERS
·
25 Nov 2024

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

THOMSON REUTERS
·
25 Nov 2024

Press Release: NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Dow Jones
·
25 Nov 2024

European Equities Traded in the US as American Depositary Fall Sharply in Tuesday Trading

MT Newswires Live
·
13 Nov 2024

NuCana PLC expected to post a loss of £2.67 a share - Earnings Preview

Reuters
·
12 Nov 2024

European Equities Traded in the US as American Depositary Move Higher in Monday Trading

MT Newswires Live
·
12 Nov 2024

NuCana Reports 'Encouraging' Data From Study to Treat Patients With Lung Cancer

MT Newswires Live
·
11 Nov 2024

NuCana announces initial data from Phase 1b/2 modular study of NUC-3373

TIPRANKS
·
11 Nov 2024

NuCana Announces Encouraging Initial Data From Phase 1B/2 Modular Study of Nuc-3373 in Combination With Pembrolizumab or Docetaxel

THOMSON REUTERS
·
11 Nov 2024

NuCana Plc - Significant Tumor Reductions in Pd-(L)1 Experienced Patients With Nuc-3373 Plus Pembrolizumab

THOMSON REUTERS
·
11 Nov 2024

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

GlobeNewswire
·
11 Nov 2024